Synopulse Weekly: Top Deals, FDA Moves & Pricing Insights
Top biopharma deals, FDA approvals, and market access news from the past week.
Breakthrough Device Designation
LifeScience Weekly Digest: Key Industry Updates (13th – 17th January)
JP Morgan Week featured notable developments in drugs, devices, diagnostics, and digital health. Johnson & Johnson paid $14.6 billion for Intra-Cellular Therapies, bolstering its neuroscience portfolio with CAPLYTA® and a strong mental health pipeline. Eli Lilly invested $2.5 billion in Scorpion Therapeutics’ PI3Kα inhibitor for hormone-positive breast cancer, while Bausch + Lomb expanded ophthalmology with … Read more
LifeScience Weekly Digest: Key Industry Updates (6th – 10th January)
In early 2025, significant developments across the biopharmaceutical and medical device sectors shaped the healthcare landscape. Stryker’s $4.9 billion acquisition of Inari Medical, Transcarent’s $621 million deal for Accolade, and several FDA designations for investigational treatments, such as Johnson & Johnson’s nipocalimab, highlight industry advancements. Medicare’s rescinding of coverage for certain cancer genetic tests and … Read more